Exelixis
EXEL
#1725
Rank
NZ$16.81 B
Marketcap
$58.86
Share price
-1.16%
Change (1 day)
57.81%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.47

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.50. In 2022 the company made an earnings per share (EPS) of $1.01 a decrease over its 2021 EPS that were of $1.31.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.47-53.64%
2022$1.01-22.97%
2021$1.31100%
2020$0.65-65.09%
2019$1.87-53.91%
2018$4.07333.96%
2017$0.94-260.61%
2016-$0.58-58.75%
2015-$1.41-42.45%
2014-$2.465.3%
2013-$2.3343.48%
2012-$1.63-264.29%
2011$0.99-165.88%
2010-$1.50-32.54%
2009-$2.23-17.65%
2008-$2.7175.86%
2007-$1.54-25.64%
2006-$2.078.33%
2005-$1.91-42.86%
2004-$3.3430.34%
2003-$2.56-5.23%
2002-$2.71-0.65%
2001-$2.72-51.88%
2000-$5.66

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$6.19 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$5.62 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$3.22 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.02 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$25.02 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$24.91 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.29 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$17.68-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.49-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA